Bexarotene-Induced Dyslipidemia and Central Hypothyroidism in a Patient With Sezary Syndrome

Barish Sariakcali, Esma Jamaspishvili, Mehtap Evran, Murat Sert, Tamer Tetiker

Abstract


We report a patient with Sezary syndrome (cutaneous T-cell lymphoma) who developed severe central hypothyroidism and mixed hyperlipidemia due to the bexarotene treatment (a synthetic retinoid analog with specific affinity for retinoid X receptor used in the treatment of Sezary syndrome). The other pituitary functions were found to be normal. These are rare adverse effects of bexarotene treatment and there are a few case reports in literature. Management of the adverse events could be done by nicotinic acid or fenofibrates, statins and L-thyroxin replacement. In this case we managed the patient by nicotinic acid, statin and L-thyroxin for 2 years.




J Endocrinol Metab. 2014;4(4):115-117
doi: http://dx.doi.org/10.14740/jem222w

Keywords


Sezary syndrome; Bexarotene; Dyslipidemia; Central hypothyroidism

Full Text: HTML PDF
 

Browse  Journals  

 

Journal of Clinical Medicine Research

Journal of Endocrinology and Metabolism

Journal of Clinical Gynecology and Obstetrics

 

World Journal of Oncology

Gastroenterology Research

Journal of Hematology

 

Journal of Medical Cases

Journal of Current Surgery

Clinical Infection and Immunity

 

Cardiology Research

World Journal of Nephrology and Urology

Cellular and Molecular Medicine Research

 

Journal of Neurology Research

International Journal of Clinical Pediatrics

 

 
       
 

Journal of Endocrinology and Metabolism, bimonthly, ISSN 1923-2861 (print), 1923-287X (online), published by Elmer Press Inc.                     
The content of this site is intended for health care professionals.
This is an open-access journal distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Creative Commons Attribution license (Attribution-NonCommercial 4.0 International CC-BY-NC 4.0)


This journal follows the International Committee of Medical Journal Editors (ICMJE) recommendations for manuscripts submitted to biomedical journals,
the Committee on Publication Ethics (COPE) guidelines, and the Principles of Transparency and Best Practice in Scholarly Publishing.

website: www.jofem.org   editorial contact: editor@jofem.org
Address: 9225 Leslie Street, Suite 201, Richmond Hill, Ontario, L4B 3H6, Canada

© Elmer Press Inc. All Rights Reserved.